The Influence of Combined Genotypes of the HLADRB1*1501 and CD24 Single Nucleotide Polymorphism on Disease Severity of Iranian Multiple Sclerosis Patients
-
Hossein Ali Ghlichnia
,
Abolghasem Kollaee
,
Majid Gaffarpoor
,
Abolfazl Movafagh
,
Babak Ghlichnia
,
Mahdi Zamani
Abstract
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. It is a clinically heterogeneous disorder especially in terms of disease severity. Current investigations suggest that genes and gene-gene interactions not only influence on susceptibility to MS but also affect the disease severity. In this study, we investigated the contribution of the HLADRB1*1501 allele and single nucleotide polymorphism (SNP) in CD24 gene and also combined genotypes of the HLADRB1*1501 and CD24 SNP to disease severity in Iranian MS patients. We have reported previously that the HLA- DRB1*1501 allele and the CD24v/v genotype associated with disease susceptibility and some other studies proposed that HLA-DRB1*1501 allele be associated with MS severity. In this study, the results showed a significant difference in the Multiple Sclerosis Severity Score (MSSS) of the nine different genotypes (F=2.838, P=0.007). Subsequent analysis revealed a statistically significant difference in the MSSS between the MS patients who were carriers of HLA-DRB1*1501/1501 and those who were not carriers of HLA-DRB1*1501/1501 genotypes (P=0.04). Moreover, the MS patients carrying combined genotypes of the HLA- DRB1*1501/x-CD24 v/v had statistically severe disease than the patients who did not carry the HLA- DRB1*1501- CD24 v/v (P=0.047). In conclusion, our findings suggest that, HLA-DRB1*1501/1501 and bigenic genotypes of the HLA- DRB1*1501/x- CD24 v/v may influence on disease severity in Iranian MS patients.
Compston A, Coles A. Multiple sclerosis. Lancet 2008;372(9648):1502-17.
Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology1994;13(1-2):1-7.
Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52(1):61-76.
Oksenberg JR, Baranzini SE, Barcellos LF, et al. Multiple sclerosis: genomic rewards. J Neuroimmunol 2001;113(2);171-84.
Zuvich RL, McCauley JL, Pericak-Vance MA, et al. Genetics and pathogenesis of multiple sclerosis. Semin Immunol 2009;21(6):328-33.
Fogdell A, Hillert J, Sachs C, et al. The multiple sclerosisand narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. Tissue Antigens 1995;46(4):333-6.
Ghabanbasani MZ, Gu XX, Spaepen M, et al. Importance of HLA-DRB1 and DQA1 genes and of the amino acid polymorphisms in the functional domain of DRB1 chain inMultiple Sclerosis. J Neuroimmonol 1995;59(1-2);77-82.
Hoffjan S, Akkad DA. The genetics of multiple sclerosis: an update 2010. Mol Cell Probes 2010;24(5):237-43.
McElroy JP, Oksenberg JR. Multiple sclerosis genetics. Curr Top Microbiol Immunol 2008;318(1):45-72.
Alcina A, Fedetz M, Ndagire D, et al. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS ONE 2009;4(1):e4137.
Ramagopalan SV, Anderson C, Sadovnick AD, et al. Genomewide study of multiple sclerosis. N Engl J Med 2007;357(21):2199-200.
Zhou Q, Wu Y, Nielsen PJ, et al. Homotypic interaction of the heat-stable antigen is not responsible for its costimulatory activity for T cell clonal expansion. Eur J Immunol 1997;27(10):2524-8.
Liu Y, Jones B, Aruffo A, Sullivan KM, Linsley PS, Janeway CA Jr. Heatstable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med 1992;175(2):437-45.
Zhou Q, Rammohan K, Lin S, et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A 2003;100(25):15041-6.
Bai XF, Li O, Zhou Q, et al. CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J Exp Med 2004;200(4):447-58.
Okda DT, Srinivasan R, Oksenberg JR, et al. GenotypeH. Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009;132(Pt 1):250-9.
Barcellos LF, Oksenberg JR, Begovich AB, et al. HLADR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003;72(3):710-6.
Sadovnick AD, Ebers GC, Dyment DA, et al. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 1996;347(9017):1728-30.
Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum.Mol. Genet 2006;15(18):2813-24.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;l50(1):121-7.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-52.
Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64(7):1144-51.
Wang L, Lin S, Rammohan KW, et al. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet 2007;3(4):e49.
Caballero A, Alve´s-Leo´n S, Papais-Alvarenga R, et al. DQB1*0602 confers genetic susceptibility to multiple sclerosisin Afro-Brazilians. Tissue Antigens 1999;54(5):524-6.
Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74(1):160-7.
Shahbazi M, Roshandel D, Ebadi H, et al. High frequency of the IL-2 -330 T/HLA-DRB1*1501 haplotype in patients with multiple sclerosis. Clin Immunol 2010;137(1):134-8.
Ramagopalan SV, Ebers GC. Epistasis: multiple sclerosis and the major histocompatibility complex. Neurology 2009;72(6):566-7.
| Files | ||
| Issue | Vol 52, No 6 (2014) | |
| Section | Articles | |
| Keywords | ||
| Multiple sclerosis HLA-DRB1*1501 CD24 MSSS | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
